Ondansetron oral dispersible film - Taho Pharma
Alternative Names: CINV-TAH4411; TAH-4411Latest Information Update: 28 Aug 2023
At a glance
- Originator TAHO Pharmaceuticals
- Class Anti-inflammatories; Antiemetics; Antipsychotics; Carbazoles; Drug withdrawal therapies; Imidazoles; Irritable bowel syndrome therapies; Obesity therapies; Small molecules; Smoking cessation therapies
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chemotherapy-induced nausea and vomiting
Most Recent Events
- 31 Jul 2023 Launched for Chemotherapy-induced nausea and vomiting in Japan (PO), prior to July 2023 (Taho Pharma pipeline, July 2023)